Type 1 Diabetes

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

Announced by the US FDA on May 19, 2023, the clearance of the iLet ACE Pump and the iLet Dosing Decision Software, when combined with a compatible CGM, will form the iLet Bionic Pancreas.

Diabetes care experts discuss practical strategies to help young adults with type 1 diabetes transition from pediatric to adult endocrinology care, and how families can support them during this transition.

Dr Julia Blanchette explains how a micro video toolkit developed by her team can help young adults alleviate the financial stress of type 1 diabetes.

Julia Blanchette, PhD, RN; Natalie Bellini, DNP, FNP-BC; and Diana Isaacs, PharmD, BC-ADM, CDCES discuss the challenges young adults with type 1 diabetes encounter, including managing their healthcare finances.

Dr Julia Blanchette highlights some of the latest advancements in automated insulin delivery systems that can aid in the self-management of type 1 diabetes.

An analysis of more than 800,000 person-years of follow-up data from people in the United Kingdom with type 1 diabetes offers an overview of cancer incidence and mortality among this cohort.

In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.

In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.

A cross-sectional analysis of Medicare and commercial insurer spending suggests the in-state biosimilar production plan could be substantial in savings even after insulin cost rebates.

An analysis of NHANES data from 2009-2020 suggest approximately 75% of people with diabetes in the US were not at the American Diabetes Association-recommended HbA1c target of less than 7%.

An analysis of data from the TEDDY study suggests increased levels of moderate to vigorous physical activity could reduce risk of progression to type 1 diabetes in multiple islet autoantibody-positive children.

An analysis of data from nearly 100 adults with type 1 diabetes details associations between chronotypes and improved well-being in people with diabetes.

Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.

An analysis of more than 4000 people from a university hospital in Japan details the impact of the COVID-19 pandemic on glycemic control and lipid profiles among people with diabetes.

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.

Drs Diana Isaacs and Natalie Bellini emphasize the need for early detection of diabetic kidney disease through the monitoring of cardiometabolic risk factors.

George Bakris, MD, shares best practices for co-management and providing comprehensive care for patients with diabetic kidney disease.

Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.

Dr George Bakris elaborates on the risk factors, monitoring, treatment objectives, and the impact of diet and exercise in preventing the progression of diabetic kidney disease.

On April 21, 2023, Medtronic announced the long-awaited US approval of their MiniMed 780G System with Smart Guard Technology and the Guardian 4 Sensor, which has been available in Europe for nearly 3 years.

An analysis of an ethnically diverse cohort in London found African Caribbean people experienced a 39% greater risk of sight-threatening DR, independent of traditional risk factors.

A meta-analysis of trials examining use of the t:slim X2 insulin pump with Control-IQ technology, results of the study indicate use of the hybrid closed loop technology was associated with improvements in glycemic control, regardless of patient age, race, or previous CGM use.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.

Announced on April 14, the clearance allows for FreeStyle Libre 3 users to obtain real-time glucose readings on a large, easy-to-see screen directly from their back of arm sensors.

An analysis of data from national registries in Sweden offers an overview of associations between psychiatric disorders and educational milestone attainment among youth with type 1 diabetes.

A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.